From economics to health outcomes: Delving into the significance of reduced insulin prices
The recent substantial price reductions in insulin therapy by major manufacturers prompt an examination of their impact on South Africa (SA)’s healthcare. While Eli Lilly, Novo Nordisk, and Sanofi cut prices on long-acting basal insulin, among others, significantly, these insulins are not on SA...
Saved in:
Main Authors: | M Leuschner, M Strydom, V Steenkamp |
---|---|
Format: | Article |
Language: | English |
Published: |
South African Medical Association
2024-08-01
|
Series: | South African Medical Journal |
Subjects: | |
Online Access: | https://samajournals.co.za/index.php/samj/article/view/2014 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic review
by: Maheeka Seneviwickrama, et al.
Published: (2025-01-01) -
Initiation of insulin therapy in patients with type 2 diabetes: An observational study
by: Zerovnik Spela, et al.
Published: (2022-03-01) -
Sick Day Management for Adults with Diabetes Who Take Insulin
by: Nancy Gal, et al.
Published: (2017-08-01) -
Sick Day Management for Adults with Diabetes Who Take Insulin
by: Nancy Gal, et al.
Published: (2017-08-01) -
Autophagy-lysosome pathway in insulin & glucagon homeostasis
by: Yi Wu, et al.
Published: (2025-02-01)